Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors

By afschroeder • November 2, 2025

Wu M, Yang S, Yang Z, Fan J, Lomeli SH, Dharanipragada P, Moriceau G, Damoiseaux R, Kelley MC, Prieto-Granada CN, Giubellino A, Nosrati M, Kashani-Sabet M, Kim KB, Johnson DB, Liu S, Lo RS. Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. Immunity. 2025 Oct 31:S1074-7613(25)00431-5. doi: 10.1016/j.immuni.2025.10.001. Epub ahead of print. PMID: 41175874.

Tags: acquired resistance, Anti-CTLA-4, Anti-PD-1, apoptosis sensitivity, copy-number variation, Dermatology, genomic evolution, immune checkpoint inhibitor, immune evasion, melanoma, Post Doc, Publications, single-cell whole-genome sequencing, T cell cytotoxicity, whole-exome sequencing

Related Posts

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib[...]

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani[...]

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study

Chen A, Krenitsky A, Perry SS, Tan KW, Swick BL, Anderson KR, Barry KK, Kelsey B, Carlberg VM, Coughlin CC, Craddock M, Fadzeyeva H, Ferringer[...]